OncoMatch/Clinical Trials/NCT06341764
Neo-adjuvant Chemo and Immunotherapy in the Pre-operAtive Treatment of Locally Advanced CholangIOcarciNoma
Is NCT06341764 recruiting? Yes, currently enrolling (Jun 2026). This Phase 2 trial studies multiple treatments for cholangiocarcinoma.
Treatment: Durvalumab 1120 mg · Durvalumab 1500 mg · Tremelimumab i.v. at 300 mg · Cisplatin (CDDP) 25 mg/mq i.v · Gemcitabine (GEM) 1000 mg/mq i.v. — Neoadjuvant chemo- and immunotherapy ameliorate the recurrence rate of cholangiocarcinoma (CCA) at 12 months after surgery.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Immunotherapy
Chemotherapy
Other
Cancer type
Cholangiocarcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: systemic therapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: local therapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: radiation therapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: radiofrequency ablation
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Cannot have received: electro-chemotherapy
No previous systemic or local treatments including radiation therapy, radiofrequency ablations, electro-chemotherapy.
Lab requirements
Blood counts
Haemoglobin ≥9.0 g/dL; ANC ≥1.5 × 10^9/L; Platelet count ≥100 × 10^9/L
Kidney function
Measured or calculated creatinine clearance >40 mL/min
Liver function
Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN
Adequate normal organ and marrow function as defined below: Haemoglobin ≥9.0 g/dL; ANC ≥1.5 × 10^9 /L; Platelet count ≥100 × 10^9/L; Serum bilirubin ≤1.5 x institutional ULN (except Gilbert's syndrome); AST (SGOT)/ALT (SGPT) ≤2.5 x ULN unless liver metastases are present, in which case ≤5x ULN; Measured or calculated creatinine clearance >40 mL/min
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT06341764 currently recruiting?
Yes, this trial is currently recruiting patients.
Can patients have received prior systemic therapy?
No. This trial requires treatment-naive patients — prior systemic therapy is an exclusion criterion.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages